Kyungbo Pharm Increases ADC Plant Investment to 96 Billion Won (66.49% of Equity)
-
Subsidiary Kyungbo Pharm increases investment for new ADC CDMO production facility from 85.46 billion won to 96 billion won (correction filing)
-
66.49% of equity (based on separate financial statements as of end-2023)
-
Investment period: 2024-08-14 to 2026-12-31
-
Purpose: Build GMP production facility for ADC CDMO business
-
Reason for increase: Equipment expansion and design changes to improve productivity
KOSPI Filing Information
-
Filing: [Correction of Description] Investment In New Facilities, Etc. (Major Management Matters Of Subsidiaries)
-
Company: CHONGKUNDANG HOLDINGS (001630)
-
Submission: CHONGKUNDANG HOLDINGS CORP.
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division